Shaodong Hong

18PUBLICATIONS
45CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Tumour immunologyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Mar 24, 2026
The Oncogenic EGFR-SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer.

Jiani Zheng, Shen Zhao, Jianhua Zhan

|Apr 22, 2025
Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study.

Jinhui Xue, Yuxiang Ma, Yuanyuan Zhao

|Oct 17, 2023
Adjuvant therapy in completely resected, EGFR-mutant non-small cell lung cancer: a comparative analysis of treatment efficacy between EGFR-TKI and anti-PD-1/PD-L1 immunotherapy.

Zichun Li, Xuanye Zhang, Yuhong Wang

|Sep 11, 2023
Deciphering transcriptomic determinants of the divergent link between PD-L1 and immunotherapy efficacy.

Anlin Li, Linfeng Luo, Wei Du

|Mar 19, 2022
Optimizing the tumor shrinkage threshold for evaluating immunotherapy efficacy for advanced non-small-cell lung cancer.

Wei Du, Chen Chen, Lin-Feng Luo

|Nov 09, 2021
PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer.

Hui Yu, Ping Chen, Liangping Xia

Pageof 3

Frequent Collaborators

3 joint publications

Gang Chen

3 joint publications

Li Zhang

3 joint publications

Wenfeng Fang

2 joint publications

Zhonghan Zhang